Patents by Inventor Christopher D. Porada

Christopher D. Porada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Post-Natal Transplantation Of Factor VIII-Expressing Cells For Treatment of Hemophilia
    Publication number: 20240139253
    Abstract: Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are isolated prenatally, at birth, or after the subject's birth. The modified MSC may also express high levels von Willebrand factor protein.
    Type: Application
    Filed: March 31, 2023
    Publication date: May 2, 2024
    Inventors: Maria Graca N.D. Almeida-Porada, Christopher D. Porada, Anthony Atala, Christopher B. Doering, H. Trent Spencer
  • IN UTERO TRANSPLANTATION OF FACTOR VIII-EXPRESSING CELLS FOR TREATMENT OF HEMOPHILIA
    Publication number: 20240066067
    Abstract: Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are injected into the subject prenatally. The modified MSC may also express high levels von Willebrand factor protein.
    Type: Application
    Filed: March 31, 2023
    Publication date: February 29, 2024
    Inventors: Maria Graca N.D. Almeida-Porada, Christopher D. Porada, Anthony Atala, Christopher B. Doering, H. Trent Spencer
  • IN UTERO TRANSPLANTATION OF FACTOR VIII-EXPRESSING CELLS FOR TREATMENT OF HEMOPHILIA
    Publication number: 20200368286
    Abstract: Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are injected into the subject prenatally. The modified MSC may also express high levels von Willebrand factor protein.
    Type: Application
    Filed: August 23, 2018
    Publication date: November 26, 2020
    Inventors: Maria Graca N.D. Almeida-Porada, Christopher D. Porada, Anthony Atala, Christopher B. Doering, H. Trent Spencer
  • POST-NATAL TRANSPLANTATION OF FACTOR VIII-EXPRESSING CELLS FOR TREATMENT OF HEMOPHILIA
    Publication number: 20200360441
    Abstract: Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are isolated prenatally, at birth, or after the subject's birth. The modified MSC may also express high levels von Willebrand factor protein.
    Type: Application
    Filed: August 23, 2018
    Publication date: November 19, 2020
    Inventors: Maria Graca N.D. Almeida-Porada, Christopher D. Porada, Anthony Atala, Christopher B. Doering, H. Trent Spencer
  • Reprogramming Mesenchymal Stromal Cells Into Hematopoietic Cells
    Publication number: 20160130554
    Abstract: Method for reprogramming of stromal cells into hematopoietic cells are provided. Also provided are mesenchymal stromal cells that can be reprogrammed into hematopoietic cells. In addition, hematopoietic cells reprogrammed from mesenchymal stromal cells are provided. Reprogramming stromal cells into hematopoietic cells is effected through a vector encoding a transcription factor that controls hematopoietic cell differentiation. Methods of treating subjects having diminished hematopoietic cell populations are provided as well.
    Type: Application
    Filed: November 4, 2015
    Publication date: May 12, 2016
    Applicant: Wake Forest University Health Sciences
    Inventors: Maria Graca N.D. Almeida-Porada, Christopher D. Porada, Colin E. Bishop